The Latest Cardiac and Vascular News
SARASOTA, Fla., Aug. 13, 2024 /PRNewswire/ — Spectrum Dynamics Medical, a leading innovator in digital SPECT-CT imaging solutions, announced that its partnering with DEEPDENSE Medical, developing innovative AI-based clinical applications to revolutionize Cardiac and Spine disease…
• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
NEW YORK, Aug. 12, 2024 /PRNewswire/ — Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announces expanded use of the CADScor System within wellness exams as part of self-insured companies’ health plans. As healthcare costs continue to rise, the CADScor System has…
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures
SAN DIEGO, Aug. 12, 2024 /PRNewswire/ — Provisio Medical, Inc., pioneers of Sonic Lumen Tomography™ (SLT) technology to provide real time blood vessel measurements during vascular interventions, today announced a key presentation featuring the Provisio™ SLT IVUS™ System during the annual…
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class
– 2nd quarter conference call to be held Tuesday, August 13th, at 8:30 a.m. ET –
CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024.
August 08, 2024 08:00 AM Eastern Daylight Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced treatment of the first two patients in the first-in-human feasibility study using its novel Cardiac Surgery […]
Clinical research study at leading U.S. hospital will further validate the efficacy of advanced, AI-powered magnetocardiography for transformative cardiac diagnostics PALO ALTO, Calif., Aug. 8, 2024 /PRNewswire/ — SandboxAQ today announced a technology collaboration with Mayo Clinic to…
